This study, utilizing 18F-FDG MicroPET/CT dynamic imaging combined with molecular biology techniques, systematically reveals, for the first time, the dual mechanism by which the SGLT2 inhibitor EMPG improves energy metabolism disorders in HF by regulating the PPARα signaling pathway. This evidence concerns the gene SLC5A2 and Disorder of energy metabolism.